Evidence map›Paper›PMID 42589502›Full record

ArticleInternational journal of molecular sciences2026

Characterization of a Novel BTD Hypomorphic Variant in a Patient with Complex Neurodevelopmental Delay: Resolving Actionable Metabolic Vulnerabilities Beyond Borderline Plasma Biochemistry.

Claudia Toledo-Pacheco, Minerva Montero-Hernández, María Pilar López-Garrido, Carles de Diego-Boguñá, Francisco Sánchez-Sánchez

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Claudia Toledo-PachecoServicio de Genética, Hospital Universitario de Toledo (HUT), 45007 Toledo, Spain.ORCID 0009-0007-5987-6583
Minerva Montero-HernándezInstituto de Biomedicina, Universidad de Castilla-La Mancha (UCLM), 02008 Albacete, Spain.
María Pilar López-GarridoInstituto de Biomedicina, Universidad de Castilla-La Mancha (UCLM), 02008 Albacete, Spain.
Carles de Diego-BoguñáServicio de Genética, Hospital Universitario de Toledo (HUT), 45007 Toledo, Spain.ORCID 0000-0001-5246-3793
Francisco Sánchez-SánchezInstituto de Biomedicina, Universidad de Castilla-La Mancha (UCLM), 02008 Albacete, Spain.

Funding

Asociación para la difusión de Avances Oncológicos CAT190273Servicio de Salud de Castilla-La Mancha CGP180358
6 · The paper itself

Abstract

Plasma biochemistry often presents significant limitations in diagnosing borderline metabolic disorders, particularly within complex neurodevelopmental phenotypes. Here, we present the clinical genomic evaluation of a six-year patient presenting with early-onset hypotonia and severe gastrointestinal complications whose newborn screening panel did not evaluate biotinidase (BTD) activity. While initial baseline plasma biochemistry yielded borderline residual BTD function (46% of the population mean), targeted sequencing identified a novel, compound heterozygous hypomorphic variant (p.Thr459Met) in

Indexed as

BiotinidaseBiotinidase DeficiencyNeurodevelopmental DisordersBiotinChildFemaleHumansMaleMutationPhenotypeBiotinBiotinidasebiotinidase deficiencyBTD genediagnostic odysseyfunctional validationhypomorphic mutationsprecision medicinevariant of uncertain significance (VUS)

Identifiers

PMID42589502
PMCPMC13467485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.